Assessment tools for chemotherapy-induced peripheral neuropathy: a narrative review of clinician, patient-reported, and objective measures
JNCI Cancer Spectrum · 2026
DOI: 10.1093/jncics/pkaf119 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JNCI Cancer Spectrum, 2026. Verfasst von Kaitlin Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Patient Reported Outcome Measures, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy, affecting motor, sensory, and autonomic function. Accurate assessment is important during treatment, when CIPN may necessitate dose reductions or discontinuation, and after treatment, as chronic CIPN can greatly impact quality of life and safety in cancer survivorship. Measurement tools can include subjective measures, including clinician-based grading scales or patient-reported outcome measures (PROMs), and objective measures. This review aimed to summarize current CIPN assessment tools, highlighting characteristics such as feasibility, minimum clinically important differences (MCIDs), validity and reliability to allow for comparison and selection of tools by clinicians and researchers.
Methods
Following the Scale for the Assessment of Narrative Review Articles methodology guidelines, 2 investigators performed a comprehensive literature search using predefined search terms relating to CIPN measurement. Additional papers were identified through a search of prior systematic reviews and tracing back references from key articles. Data were extracted from source papers and any available appendices.
Results
We identified 3 clinician-based grading scales, 20 PROMs, and 8 objective measurement tools. While the majority of tools have been validated for neuropathy, a minority of them have established MCIDs and validation in CIPN-specific populations.
Conclusions
Tool selection should align with the specific needs of clinicians and researchers. Instruments that are valid, reliable, and assess multiple CIPN domains are recommended. Further research is needed to validate many of these tools in CIPN-specific populations and to determine their MCIDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Institute of Medical Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
- Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Physical Medicine and Rehabilitation, Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada.
ORCID-Profile: Kaitlin Chen, Eric Antonen, Michelle B Nadler, Jennifer M Jones
Zitieren
APA
Chen, K., Antonen, E., Nadler, M. B., Mauti, E., & Jones, J. M. (2026). Assessment tools for chemotherapy-induced peripheral neuropathy: a narrative review of clinician, patient-reported, and objective measures. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf119
Vancouver
Chen K, Antonen E, Nadler MB, Mauti E, Jones JM. Assessment tools for chemotherapy-induced peripheral neuropathy: a narrative review of clinician, patient-reported, and objective measures. JNCI Cancer Spectrum. 2026. doi:10.1093/jncics/pkaf119
BibTeX
@article{Chen2026,
author = {Chen, Kaitlin and Antonen, Eric and Nadler, Michelle B and Mauti, Emma and Jones, Jennifer M},
title = {Assessment tools for chemotherapy-induced peripheral neuropathy: a narrative review of clinician, patient-reported, and objective measures},
journal = {JNCI Cancer Spectrum},
year = {2026},
doi = {10.1093/jncics/pkaf119}
}
EUVIMED